Adipose-derived Stem Cells Combined With Excimer Light in the Treatment of Stable Vitiligo

Tanta University15 enrolled

Overview

This study aimed to assess the efficacy and safety of intradermal injection of adipose-derived stem cells, alone and combined with excimer light in treatment of stable vitiligo.

Vitiligo is a common disfiguring autoimmune disease that negatively affects patients' self-esteem and quality of life. Vitiligo is caused by a dynamic interplay between genetic and environmental risks that initiates an autoimmune attack on melanocytes in the skin. Adipose tissue-derived stem cells have the capacity to secrete a variable cytokines and growth factors, including hepatocyte growth factor (HGF), interleukin-6 (IL-6), macrophage colony-stimulating factor (M-CSF), transforming growth factor-β1 (TGF-β1), tumour necrosis factor (TNF), vascular endothelial growth factor (VEGF), that stimulate angiogenesis, tissue remodeling, and anti-apoptotic processes. Phototherapy has an eminent effect on stoppage of progression and repigmentaion of vitiligo patches. Narrowband ultraviolet B (NB-UVB) and ultraviolet A (UVA), and monochromatic excimer light (MEL) can be used in treatment of vitiligo. The specific 308-nm radiation wavelength is delivered in a targeted form by the xenon-chloride excimer laser and is also available in an incoherent form that is commonly referred to as the excimer lamp.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Adipose-derived Stem Cells Excimer Light Stable Vitiligo

Interventions

Adipose-derived Stem Cells Combined With Excimer LightPROCEDURE

All patients received adipose-derived stem cells combined with excimer light.

Eligibility

Sex: ALLMin age: 15 YearsMax age: 52 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with two or more similar patches of stable vitiligo "absence of new patches of depigmentation or enlargement of the pre-existing patches" for 6 months at least. * Patients who will accept to be enrolled in the study and will sign an informed consent. Exclusion Criteria: * Unstable vitiligo for more than 6 months. * Current bacterial or viral infection in the treatment area. * Patients with unrealistic expectation. * Very thin patients "poor donor areas". * Patients with uncontrolled systemic disease such as diabetes or hypertension. * Patients with hepatitis B or C virus infection. * Patients with any other skin disease. * Patients with bleeding or coagulopathy disorders. * Pregnancy and lactation. * Patients who received topical treatment for vitiligo during the last month, or systemic treatment during the past three months before the study.

Locations (1)

Tanta University

Tanta, El-Gharbia, Egypt

Outcomes

Primary Outcomes

Vitiligo Disease Activity (VIDA) Score

The Vitiligo Disease Activity (VIDA) Score is a 6-point clinical scale used to measure the progression or stability of vitiligo. The scale ranges from -1 to +4, where higher numbers indicate more recent and rapid disease activity: * 4: Active disease (new lesions or expansion) within the last 6 weeks. * 3: Active disease between 6 weeks and 3 months. * 2: Active disease between 3 and 6 months. * 1: Active disease between 6 and 12 months. 0: Stable disease with no changes for 1 year or longer. * 1: Stable for 1 year or longer, showing signs of spontaneous repigmentation

Time frame: 6 months post-procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.